MCID: DLT002
MIFTS: 76

Dilated Cardiomyopathy

Categories: Rare diseases, Cardiovascular diseases, Genetic diseases, Neuronal diseases, Ear diseases

Aliases & Classifications for Dilated Cardiomyopathy

MalaCards integrated aliases for Dilated Cardiomyopathy:

Name: Dilated Cardiomyopathy 37 12 72 23 49 36 28 51 14
Familial Dilated Cardiomyopathy 12 72 49 24 28 69
Idiopathic Dilation Cardiomyopathy 12 72 69
Cardiomyopathy, Dilated 28 41 69
Primary Dilated Cardiomyopathy 12 28
Congestive Cardiomyopathy 12 24
Dcm 49 44
Hypokinetic Dilated Cardiomyopathy, Familial 49
Primary Familial Dilated Cardiomyopathy 24
Cardiomyopathy, Familial Idiopathic 69
Familial Idiopathic Cardiomyopathy 24
Idiopathic Dilated Cardiomyopathy 49
Cardiomyopathy, Familial Dilated 49
Dilated Cardiomyopathy, Familial 49
Fdc 24

Classifications:



External Ids:

Disease Ontology 12 DOID:12930
ICD10 32 I42.0
MeSH 41 D002311
NCIt 46 C84673
KEGG 36 H00294

Summaries for Dilated Cardiomyopathy

NIH Rare Diseases : 49 Dilated cardiomyopathy (DCM) is a disease of the heart muscle which primarily affects the heart's main pumping chamber, the left ventricle. It is the most common type of cardiomyopathy and typically affects those aged 20 to 60. The left ventricle of affected individuals becomes enlarged (dilated) and cannot pump blood to the body with as much force as a healthy heart can. The heart muscle also has difficulty contracting normally, which can lead to irregular heartbeats (arrhythmia), blood clots, or sudden death. Over time, the heart becomes weaker and heart failure can occur. While the cause of dilated cardiomyopathy is often unknown (idiopathic), some cases are acquired and roughly half are inherited or familial. Also, DCM can be a feature of many genetic syndromes. Familial dilated cardiomyopathy is most often inherited in an autosomal dominant pattern. Familial dilated cardiomyopathy is caused by mutations in several different genes, most commonly in the TTN gene (found in about 20% of cases). DCM treatment may include medication, pacemakers, implantable cardiac defibrillators, or heart transplantation.  Last updated: 1/2/2017

MalaCards based summary : Dilated Cardiomyopathy, also known as familial dilated cardiomyopathy, is related to familial isolated dilated cardiomyopathy and cardiomyopathy, dilated, 1e. An important gene associated with Dilated Cardiomyopathy is LMNA (Lamin A/C), and among its related pathways/superpathways are Dilated cardiomyopathy (DCM) and Cardiac conduction. The drugs Carvedilol and Verapamil have been mentioned in the context of this disorder. Affiliated tissues include Heart and Heart, and related phenotypes are cardiovascular system and homeostasis/metabolism

Disease Ontology : 12 An intrinsic cardiomyopathy that is characterized by an an enlarged heart and damage to the myocardium causing the heart to pump blood inefficiently.

Wikipedia : 72 Dilated cardiomyopathy (DCM) is a condition in which the heart becomes enlarged and cannot pump blood... more...

GeneReviews: NBK1309

Related Diseases for Dilated Cardiomyopathy

Diseases in the Dilated Cardiomyopathy family:

Cardiomyopathy, Dilated, 1a Cardiomyopathy, Dilated, 3b
Cardiomyopathy, Dilated, 1b Cardiomyopathy, Dilated, 1e
Cardiomyopathy, Dilated, 1d Cardiomyopathy, Dilated, 1g
Cardiomyopathy, Dilated, 1h Cardiomyopathy, Dilated, 1i
Cardiomyopathy, Dilated, 1j Cardiomyopathy, Dilated, 1k
Cardiomyopathy, Dilated, 1l Cardiomyopathy, Dilated, 1m
Cardiomyopathy, Dilated, 1o Cardiomyopathy, Dilated, 1p
Cardiomyopathy, Dilated, 1q Cardiomyopathy, Dilated, 1w
Cardiomyopathy, Dilated, 1x Cardiomyopathy, Dilated, 1z
Cardiomyopathy, Dilated, 2a Cardiomyopathy, Dilated, 1bb
Cardiomyopathy, Dilated, 1cc Cardiomyopathy, Dilated, 1dd
Cardiomyopathy, Dilated, 1ee Cardiomyopathy, Dilated, 1ff
Cardiomyopathy, Dilated, 1r Cardiomyopathy, Dilated, 1gg
Cardiomyopathy, Dilated, 1u Cardiomyopathy, Dilated, 1v
Cardiomyopathy, Dilated, 1hh Cardiomyopathy, Dilated, 2b
Cardiomyopathy, Dilated, 1ii Cardiomyopathy, Dilated, 1jj
Cardiomyopathy, Dilated, 1kk Cardiomyopathy, Dilated, 1nn
Dilated Cardiomyopathy 1t Cardiomyopathy Due to Anthracyclines

Diseases related to Dilated Cardiomyopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 362)
# Related Disease Score Top Affiliating Genes
1 familial isolated dilated cardiomyopathy 35.4 ACTC1 BAG3 CSRP3 DES LDB3 MYBPC3
2 cardiomyopathy, dilated, 1e 34.7 DES DSP LMNA MYH7 RBM20 SCN5A
3 cardiomyopathy, dilated, 1dd 34.1 RBM20 TNNT2
4 peripartum cardiomyopathy 33.6 MYH7 SCN5A TTN
5 myopathy, myofibrillar, 1 32.8 DES LDB3
6 hypertrophic cardiomyopathy 32.3 ACTC1 CSRP3 DES LMNA MYBPC3 MYH7
7 heart disease 32.0 ACTC1 DSP LMNA MYBPC3 MYH7 SCN5A
8 myopathy 32.0 BAG3 DES LDB3 LMNA MYH7 TAZ
9 left ventricular noncompaction 31.9 ACTC1 CSRP3 LDB3 LMNA MYBPC3 MYH7
10 cardiac conduction defect 31.7 DSP MYBPC3 MYH7 SCN5A
11 muscular dystrophy 31.7 DES LMNA SGCD TTN
12 endocardial fibroelastosis 31.6 CSRP3 MYH7 TAZ
13 muscular dystrophy, duchenne type 31.5 SGCD TNNI3 TNNT2 TTN
14 arrhythmogenic right ventricular cardiomyopathy 31.4 DES DSP LDB3 LMNA PLN SCN5A
15 restrictive cardiomyopathy 31.4 ACTC1 DES MYBPC3 MYH7 TNNI3 TNNT2
16 atrial standstill 1 31.2 DES DSP LMNA MYBPC3 MYH7 PLN
17 myofibrillar myopathy 31.0 BAG3 DES LDB3 TTN
18 aortic valve disease 2 30.9 DSP MYH7 TNNI3
19 cardiac arrest 30.9 MYH7 SCN5A TNNT2
20 limb-girdle muscular dystrophy 30.7 LMNA SGCD TTN
21 dilated cardiomyopathy 1t 12.3
22 cardiac conduction disease with or without dilated cardiomyopathy 12.3
23 cardiomyopathy, dilated, 3b 12.3
24 ventricular tachycardia, catecholaminergic polymorphic, 1, with or without atrial dysfunction and/or dilated cardiomyopathy 12.2
25 dmd-related dilated cardiomyopathy 12.2
26 cardiomyopathy, dilated, 1b 12.2
27 lmna-related dilated cardiomyopathy 12.1
28 cardiomyopathy, dilated, with woolly hair and keratoderma 12.1
29 cardiomyopathy, dilated, 1o 12.1
30 cardiomyopathy, dilated, 1x 12.1
31 3-methylglutaconic aciduria, type v 12.0
32 cardiomyopathy, dilated, with hypergonadotropic hypogonadism 12.0
33 cardiomyopathy, dilated, 1j 11.9
34 cardiomyopathy, dilated, 1l 11.9
35 cardiomyopathy, dilated, 1c, with or without left ventricular noncompaction 11.9
36 cardiomyopathy, dilated, 1g 11.9
37 cardiomyopathy, dilated, 1h 11.9
38 cardiomyopathy, dilated, 1p 11.9
39 cardiomyopathy, dilated, 1aa, with or without left ventricular noncompaction 11.9
40 cardiomyopathy, dilated, 1a 11.8
41 cardiomyopathy, dilated, 1d 11.8
42 cardiomyopathy, dilated, 1i 11.8
43 cardiomyopathy, dilated, 1m 11.8
44 cardiomyopathy, dilated, 1w 11.8
45 cardiomyopathy, dilated, 1z 11.8
46 cardiomyopathy, dilated, 2a 11.8
47 cardiomyopathy, dilated, 1bb 11.8
48 cardiomyopathy, dilated, 1cc 11.8
49 cardiomyopathy, dilated, 1ee 11.8
50 cardiomyopathy, dilated, 1ff 11.8

Graphical network of the top 20 diseases related to Dilated Cardiomyopathy:



Diseases related to Dilated Cardiomyopathy

Symptoms & Phenotypes for Dilated Cardiomyopathy

MGI Mouse Phenotypes related to Dilated Cardiomyopathy:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.16 TAZ DSP TNNI3 TNNT2 LDB3 TTN
2 homeostasis/metabolism MP:0005376 9.93 DES EYA4 TNNT2 LDB3 TTN LMNA
3 mortality/aging MP:0010768 9.77 DSP TNNI3 EYA4 TNNT2 LDB3 TTN
4 muscle MP:0005369 9.5 DSP TNNI3 TNNT2 LDB3 TTN LMNA

Drugs & Therapeutics for Dilated Cardiomyopathy

Drugs for Dilated Cardiomyopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 138)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carvedilol Approved, Investigational Phase 4,Phase 2 72956-09-3 2585
2
Verapamil Approved Phase 4 52-53-9 2520
3
Amlodipine Approved Phase 4 88150-42-9 2162
4
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
5
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
6
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
7
Enalapril Approved, Vet_approved Phase 4,Phase 2,Phase 3 75847-73-3 40466924 5362032
8
Enalaprilat Approved Phase 4,Phase 2,Phase 3 76420-72-9 6917719
9
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
10
Metoprolol Approved, Investigational Phase 4,Phase 2 51384-51-1, 37350-58-6 4171
11
Doxazosin Approved Phase 4 74191-85-8 3157
12
Allopurinol Approved Phase 4,Phase 1,Phase 2 315-30-0 2094
13
Adenosine Approved, Investigational Phase 4,Phase 1,Phase 2 58-61-7 60961
14
Regadenoson Approved, Investigational Phase 4 313348-27-5 219024
15
Spironolactone Approved Phase 4,Phase 3,Phase 2 1952-01-7, 52-01-7 5833
16
Nitric Oxide Approved Phase 4 10102-43-9 145068
17
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 4 303-98-0 5281915
18
Uric Acid Experimental, Investigational Phase 4 69-93-2 1175
19 Adrenergic beta-Antagonists Phase 4,Phase 3,Phase 2
20 Angiotensin-Converting Enzyme Inhibitors Phase 4,Phase 2,Phase 3
21 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1
22 Adrenergic alpha-1 Receptor Antagonists Phase 4
23 Adrenergic alpha-Antagonists Phase 4
24 Adrenergic Antagonists Phase 4,Phase 3,Phase 2
25 Anti-Arrhythmia Agents Phase 4
26 Antihypertensive Agents Phase 4,Phase 2,Phase 3
27 calcium channel blockers Phase 4,Phase 2
28 Calcium, Dietary Phase 4,Phase 3,Phase 2
29 Neurotransmitter Agents Phase 4,Phase 2,Phase 1
30 Vasodilator Agents Phase 4,Phase 3,Phase 2
31 Angiotensin II Type 1 Receptor Blockers Phase 4
32 Angiotensin Receptor Antagonists Phase 4
33 Angiotensinogen Phase 4
34 diuretics Phase 4,Phase 3,Phase 2
35 insulin Phase 4
36 Insulin, Globin Zinc Phase 4
37 Natriuretic Agents Phase 4,Phase 3
38 Sodium Chloride Symporter Inhibitors Phase 4
39 HIV Protease Inhibitors Phase 4,Phase 2,Phase 3
40
protease inhibitors Phase 4,Phase 2,Phase 3
41 Diuretics, Potassium Sparing Phase 4,Phase 3,Phase 2
42 Micronutrients Phase 4
43 Trace Elements Phase 4
44 Ubiquinone Phase 4
45 Vitamins Phase 4
46 Adrenergic beta-1 Receptor Antagonists Phase 4
47 Autonomic Agents Phase 4,Phase 1,Phase 2
48 Peripheral Nervous System Agents Phase 4,Phase 1,Phase 2
49 Sympatholytics Phase 4
50 Natriuretic Peptide, Brain Phase 4

Interventional clinical trials:

(show top 50) (show all 177)

# Name Status NCT ID Phase Drugs
1 Danish ICD Study in Patients With Dilated Cardiomyopathy Unknown status NCT00542945 Phase 4
2 Therapy With Verapamil or Carvedilol in Chronic Heart Failure Unknown status NCT00374465 Phase 4 Verapamil;Carvedilol
3 Regression of Fatty Heart by Valsartan Therapy Unknown status NCT00745953 Phase 4 Valsartan;Hydrochlorothiazide
4 Coenzyme Q10 Supplementation in Children With Idiopathic Dilated Cardiomyopathy Completed NCT02115581 Phase 4 Coenzyme Q10;Placebo
5 Supramaximal Titrated Inhibition of RAAS in Dilated Cardiomyopathy Completed NCT01917149 Phase 4 Benazepril;Valsartan;Metoprolol
6 Study of Qiliqiangxin Capsule to Treat Dilated Cardiomyopathy Completed NCT01293903 Phase 4 Qiliqiangxin capsule;Placebo
7 Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart Completed NCT01798992 Phase 4 Carvedilol;Metoprolol succinate;Metoprolol succinate + doxazosin
8 ACC - Atrial Contribution to CRT Completed NCT00180323 Phase 4
9 A Randomized Trial of Carvedilol in Chronic Chagas Cardiomyopathy Completed NCT01557140 Phase 4 RASi plus carvedilol
10 Effects of Allopurinol on Diastolic Function in Chronic Heart Failure Patients Completed NCT00477789 Phase 4 allopurinol
11 Effects of Early Statin Treatment After Acute Myocardial Infarction (AMI) in Japanese Patients Completed NCT00128024 Phase 4 lipid-lowering treatment
12 Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve Recruiting NCT03249272 Phase 4 Regadenoson;Adenosine
13 (MitraClip in Non-Responders to Cardiac Resynchronization Therapy) Recruiting NCT02592889 Phase 4
14 Pulse Reduction On Beta-blocker and Ivabradine Therapy Recruiting NCT02973594 Phase 4 Ivabradine;Placebo
15 Effect of Aldosterone on Energy Starvation in Heart Failure Active, not recruiting NCT00574119 Phase 4 spironolactone
16 Efficacy of Implantable Cardioverter Defibrillator in Patients With Non-ischemic Systolic Heart Failure on Mortality Active, not recruiting NCT00541268 Phase 4
17 NORDIC: Nitric Oxide-Derived Oxidants and Regional Endothelial and Diastolic Dysfunction in Dilated Cardiomyopathy Terminated NCT00293137 Phase 4
18 Cardiac Sarcoidosis Response To Steroids Trial Withdrawn NCT01210677 Phase 4 Prednisone
19 Infusion Intracoronary of Mononuclear Autologous Adult no Expanded Stem Cells of Bone Marrow on Functional Recovery in Patients With Idiopathic Dilated Cardiomyopathy and Heart Failure. Unknown status NCT02033278 Phase 2, Phase 3 Infusion of autologous mononuclear bone marrow cells;Placebo infusion
20 Orodispersible Minitablets of Enalapril in Children With Heart Failure Due to Dilated Cardiomyopathy Unknown status NCT02652728 Phase 2, Phase 3 Enalapril Orodispersible Minitablet
21 Honey in Idiopathic Dilated Cardiomyopathy Completed NCT02987322 Phase 2, Phase 3
22 Cell Therapy In Dilated Cardiomyopathy Completed NCT00333827 Phase 3 optimal therapy for cardiaca failure
23 Autologous Transplantation of Bone Marrow Mononuclear Stem-Cells for Dilated Cardiomyopathy Completed NCT00743639 Phase 2, Phase 3
24 Repetitive Intramyocardial CD34+ Cell Therapy in Dilated Cardiomyopathy (REMEDIUM) Completed NCT02248532 Phase 2, Phase 3
25 PUFAs and Left Ventricular Function in Heart Failure Completed NCT01223703 Phase 3 n-3 PUFAs;Placebo
26 A Randomized, Controlled Study to Evaluate Algisyl-LVR™ as a Method of Left Ventricular Augmentation for Heart Failure Completed NCT01311791 Phase 2, Phase 3 Standard medical therapy
27 Effect of Rosuvastatin on Left Ventricular Remodeling Completed NCT00505154 Phase 3 Rosuvastatin;placebo
28 The Acute Effects of the Angiotensin-converting Enzyme Inhibitor Enalaprilat on Flow Distribution Completed NCT00741156 Phase 3 Enalaprilat
29 Continues Positive Airway Pressure Treatment for Patients With Dilated Cardiomyopathy and Obstructive Sleep Apnea Recruiting NCT02989181 Phase 3
30 PHOspholamban RElated CArdiomyopathy STudy - Intervention Recruiting NCT01857856 Phase 3 Eplerenone
31 CHICAMOCHA 3 - Equivalence of Usual Interventions for Trypanosomiasis (EQUITY) Recruiting NCT02369978 Phase 2, Phase 3 Nifurtimox;Benznidazole;Placebo
32 A Study of ARRY-371797 in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation Not yet recruiting NCT03439514 Phase 3 ARRY-371797
33 Follow-up Safety Trial in Children With Chronic Heart Failure Therapy Receiving Orodispersible Minitablets of Enalapril Not yet recruiting NCT02654678 Phase 2, Phase 3 Enalapril Orodispersible Minitablet
34 PREclinical Mutation CARriers From Families With DIlated Cardiomyopathy and ACE Inhibitors Terminated NCT01583114 Phase 3 perindopril;placebo
35 Cell Therapy in Chagas Cardiomyopathy Terminated NCT00349271 Phase 3 Filgrastime (G-CSF);Standart therapy
36 Effectiveness of Surgical Mitral Valve Repair Versus Medical Treatment for People With Significant Mitral Regurgitation and Non-ischemic Congestive Heart Failure Terminated NCT00608140 Phase 3 Optimal medical therapy (OMT)
37 Intramuscular Injection of Mesenchymal Stem Cell for Treatment of Children With Idiopathic Dilated Cardiomyopathy Unknown status NCT01219452 Phase 1, Phase 2
38 A Pilot Trial of Ranolazine to Treat Patients With Dilated Cardiomyopathy Unknown status NCT02133911 Phase 2 Ranolazine
39 Intracoronary Autologous Mesenchymal Stem Cells Implantation in Patients With Ischemic Dilated Cardiomyopathy Unknown status NCT01720888 Phase 2
40 Study of the Acute Effects of Triheptanoin in Heart Failure Unknown status NCT01787851 Phase 1, Phase 2 Triheptanoin oil
41 Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy Completed NCT01020968 Phase 2
42 Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM) Completed NCT00765518 Phase 2
43 Safety and Efficacy Study of Stem Cell Transplantation to Treat Dilated Cardiomyopathy Completed NCT00629018 Phase 2 Bone Marrow Stimulation
44 Safety and Efficacy Study of Intramyocardial Stem Cell Therapy in Patients With Dilated Cardiomyopathy Completed NCT01350310 Phase 2
45 Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy Completed NCT01302171 Phase 2 granulocyte colony stimulating factor (GCSF)
46 Intracoronary Infusion of Autologous Bone Marrow Cells for Treatment of Idiopathic Dilated Cardiomyopathy Completed NCT00629096 Phase 2
47 PercutaneOus StEm Cell Injection Delivery Effects On Neomyogenesis in Dilated CardioMyopathy (The POSEIDON-DCM Study) Completed NCT01392625 Phase 1, Phase 2
48 Autologous Transplantation of Bone Marrow Mononuclear Stem-Cells by Mini-Thoracotomy Completed NCT00615394 Phase 1, Phase 2
49 Safety and Feasibility of Algisyl-LVR™ as a Method of Left Ventricular Restoration in Patients With DCM Undergoing Open-heart Surgery Completed NCT00847964 Phase 2
50 A Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy Completed NCT02057341 Phase 2 ARRY-371797, p38 inhibitor; oral

Search NIH Clinical Center for Dilated Cardiomyopathy

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Dilated Cardiomyopathy cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: cardiomyopathy, dilated

Genetic Tests for Dilated Cardiomyopathy

Genetic tests related to Dilated Cardiomyopathy:

# Genetic test Affiliating Genes
1 Primary Dilated Cardiomyopathy 28 ABCC9 ACTC1 ACTN2 ANKRD1 BAG3 CSRP3 DES DSG2 EYA4 FKTN LDB3 LMNA MYBPC3 MYH6 NEXN PLN PSEN1 PSEN2 RBM20 SGCD TAZ TCAP TMPO TNNT2 TPM1 TTN VCL
2 Dilated Cardiomyopathy 28
3 Cardiomyopathy, Dilated 28

Anatomical Context for Dilated Cardiomyopathy

MalaCards organs/tissues related to Dilated Cardiomyopathy:

38
Heart, Bone, Bone Marrow, Endothelial, Brain, Testes, Monocytes
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Dilated Cardiomyopathy:
# Tissue Anatomical CompartmentCell Relevance
1 Heart Myocardium Cardiomyocytes Affected by disease
2 Heart Left Ventricle Cardiomyocytes Potential therapeutic candidate, affected by disease
3 Blood Cord Blood Mesenchymal Stem Cells Potential therapeutic candidate
4 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate

Publications for Dilated Cardiomyopathy

Articles related to Dilated Cardiomyopathy:

(show top 50) (show all 1661)
# Title Authors Year
1
GDF-15 is a better complimentary marker for risk stratification of arrhythmic death in non-ischaemic, dilated cardiomyopathy than soluble ST2. ( 29397580 )
2018
2
Influence of LGALS3 gene polymorphisms on susceptibility and prognosis of dilated cardiomyopathy in a Northern Han Chinese population. ( 29129812 )
2018
3
Correlations of GDF-15 with sST2, MMPs, and worsening functional capacity in idiopathic dilated cardiomyopathy: Can we gain new insights into the pathophysiology? ( 29375722 )
2018
4
ZBTB17 loss-of-function mutation contributes to familial dilated cardiomyopathy. ( 29445930 )
2018
5
Dilated cardiomyopathy complicated with visceral heterotaxy. ( 29040450 )
2018
6
Pediatric Dilated Cardiomyopathy-Associated<i>LRRC10</i>(Leucine-Rich Repeat-Containing 10) Variant Reveals LRRC10 as an Auxiliary Subunit of Cardiac L-Type Ca<sup>2+</sup>Channels. ( 29431102 )
2018
7
Fast apixaban-related resolution of left ventricular thrombi in a patient with dilated cardiomyopathy. ( 29374418 )
2018
8
Torsion Mechanics as an Indicator of More Advanced Left Ventricular Systolic Dysfunction in Secondary Mitral Regurgitation in Patients with Dilated Cardiomyopathy: A 2D Speckle-Tracking Analysis. ( 29408823 )
2018
9
Clinical Course and Treatment of Dilated Cardiomyopathy During Twenty Years of Follow-up. ( 29416222 )
2018
10
Atypical Presentation of a Large Pericardial Effusion after Heart Transplantation in a Patient with Dilated Cardiomyopathy. ( 29429930 )
2018
11
The relationship between myocardial fibrosis and myocardial microRNAs in dilated cardiomyopathy: A link between mir-133a and cardiovascular events. ( 29377565 )
2018
12
Identification of cardiac long non-coding RNA profile in human dilated cardiomyopathy. ( 29365080 )
2018
13
No Obesity Paradox in Pediatric Patients With Dilated Cardiomyopathy. ( 29428438 )
2018
14
CD34<sup>+</sup>Cell Transplantation Improves Right Ventricular Function in Patients with Nonischemic Dilated Cardiomyopathy. ( 29380563 )
2018
15
The pathogenic gene screening in a Chinese familial dilated cardiomyopathy pedigree from Hubei. ( 29109008 )
2018
16
Contractile reserve as a predictor of prognosis in patients with non-ischaemic systolic heart failure and dilated cardiomyopathy: a systematic review and meta-analysis. ( 29258998 )
2018
17
Cardiac Nestin<sup>+</sup>Cells Derived from Early Stage of Dilated Cardiomyopathy Enhanced the Survival of the Doxorubicin-Injured Cardiac Muscle HL-1 Cells. ( 29375111 )
2018
18
Cardiac specific expression of a88H2-R15 mini-dystrophin normalized all ECG abnormalities and the end-diastolic volume in a 23-m-old mouse model of Duchenne dilated cardiomyopathy. ( 29433343 )
2018
19
Dilated Cardiomyopathy: Genetic Determinants and Mechanisms. ( 28912180 )
2017
20
12-month patterns of serum markers of collagen synthesis, transforming growth factor and connective tissue growth factor are similar in new-onset and chronic dilated cardiomyopathy in patients both with and without cardiac fibrosis. ( 28460256 )
2017
21
Breast Cancer Clinical Trial of Chemotherapy and Trastuzumab: Potential Tool to Identify Cardiac Modifying Variants of Dilated Cardiomyopathy. ( 29367538 )
2017
22
Distribution of strain patterns in children with dilated cardiomyopathy. ( 28480564 )
2017
23
Recessive TAF1A mutations reveal ribosomopathy in siblings with end-stage pediatric dilated cardiomyopathy. ( 28472305 )
2017
24
Genotype-specific pathogenic effects in human dilated cardiomyopathy. ( 28436080 )
2017
25
Risk Stratification in Dilated Cardiomyopathy: Is the Arrhythmogenic Substrate Stable Over Time? ( 28449801 )
2017
26
Life saving ICD activation in a high risk early heart failure Dilated Cardiomyopathy patient. Is it time to reconsider our primary prevention approach? ( 28951196 )
2017
27
CASZ1 loss-of-function mutation contributes to familial dilated cardiomyopathy. ( 28099117 )
2017
28
Insights from Second-Line Treatments for Idiopathic Dilated Cardiomyopathy. ( 29367542 )
2017
29
Comparison of clinical outcomes in peripartum cardiomyopathy and age-matched dilated cardiomyopathy: A 15-year nationwide population-based study in Asia. ( 28489799 )
2017
30
Genetic epidemiology of titin-truncating variants in the etiology of dilated cardiomyopathy. ( 28510119 )
2017
31
CD4(+) A CD25(+) A GARP(+) regulatory T cells display a compromised suppressive function in patients with dilated cardiomyopathy. ( 28207945 )
2017
32
The Hemodynamic Effects and Safety of Repetitive Levosimendan Infusions on Children With Dilated Cardiomyopathy. ( 28033083 )
2017
33
Tead1 is required for maintaining adult cardiomyocyte function, and its loss results in lethal dilated cardiomyopathy. ( 28878117 )
2017
34
In-depth proteomic profiling of left ventricular tissues in human end-stage dilated cardiomyopathy. ( 28427148 )
2017
35
A retrospective observational study of patients with dilated cardiomyopathy undergoing non-cardiac surgery. ( 28911292 )
2017
36
Titin Truncating Variants in Dilated Cardiomyopathy - Prevalence and Genotype-Phenotype Correlations. ( 28045975 )
2017
37
Serum paraoxonase activity in patients with ischaemic and nonischaemic dilated cardiomyopathy. ( 28899213 )
2017
38
Response Gene to Complement-32 Promotes the Imbalance of Treg/Th17 in Patients with Dilated Cardiomyopathy. ( 29035886 )
2017
39
Formation of a TBX20-CASZ1 protein complex is protective against dilated cardiomyopathy and critical for cardiac homeostasis. ( 28945738 )
2017
40
"Graded" epidural anesthesia for renal transplant in a patient with dilated cardiomyopathy and severe left ventricle systolic dysfunction. ( 28442964 )
2017
41
Myofilament remodeling and function is more impaired in peripartum cardiomyopathy compared to dilated cardiomyopathy and ischemic heart disease. ( 28935576 )
2017
42
A novel c.563 T>G, p.L189R lamin A/C mutation in identical twins with dilated cardiomyopathy. ( 26951916 )
2017
43
Propionic acidemia as a cause of adult-onset dilated cardiomyopathy. ( 28853722 )
2017
44
Addressing Health Disparities in Idiopathic Dilated Cardiomyopathy. ( 28868530 )
2017
45
Novel Genetic Variants in BAG3 and TNNT2 in a Swedish Family with a History of Dilated Cardiomyopathy and Sudden Cardiac Death. ( 28669108 )
2017
46
Intercalated disc in failing hearts from patients with dilated cardiomyopathy: Its role in the depressed left ventricular function. ( 28934278 )
2017
47
Natural genetic variation of the cardiac transcriptome in non-diseased donors and patients with dilated cardiomyopathy. ( 28903782 )
2017
48
Contrast-enhanced T1 mapping-based extracellular volume fraction independently predicts clinical outcome in patients with non-ischemic dilated cardiomyopathy: a prospective cohort study. ( 28439651 )
2017
49
Diagnostic Yield of Whole Exome Sequencing in Pediatric Dilated Cardiomyopathy. ( 29367541 )
2017
50
Truncating Variants in Titin Independently Predict Early Arrhythmias in Patients With Dilated Cardiomyopathy. ( 28494986 )
2017

Variations for Dilated Cardiomyopathy

ClinVar genetic disease variations for Dilated Cardiomyopathy:

6 (show top 50) (show all 90)
# Gene Variation Type Significance SNP ID Assembly Location
1 SCN5A NM_000335.4(SCN5A): c.4780G> C (p.Asp1594His) single nucleotide variant Pathogenic rs137854607 GRCh37 Chromosome 3, 38595800: 38595800
2 TNNT2 NM_001001430.2(TNNT2): c.421C> T (p.Arg141Trp) single nucleotide variant Pathogenic/Likely pathogenic rs74315379 GRCh37 Chromosome 1, 201333464: 201333464
3 TTN NM_001256850.1(TTN): c.2926T> C (p.Trp976Arg) single nucleotide variant Pathogenic rs267607155 GRCh37 Chromosome 2, 179647707: 179647707
4 PLN NM_002667.4(PLN): c.25C> T (p.Arg9Cys) single nucleotide variant Pathogenic rs111033559 GRCh37 Chromosome 6, 118880109: 118880109
5 PLN NM_002667.4(PLN): c.116T> G (p.Leu39Ter) single nucleotide variant Pathogenic/Likely pathogenic rs111033560 GRCh37 Chromosome 6, 118880200: 118880200
6 MYH7 NM_000257.3(MYH7): c.1594T> C (p.Ser532Pro) single nucleotide variant Pathogenic rs121913642 GRCh37 Chromosome 14, 23897088: 23897088
7 LMNA NM_170707.3(LMNA): c.16C> T (p.Gln6Ter) single nucleotide variant Pathogenic rs61046466 GRCh37 Chromosome 1, 156084725: 156084725
8 LMNA NM_170707.3(LMNA): c.585C> G (p.Asn195Lys) single nucleotide variant Pathogenic rs28933091 GRCh37 Chromosome 1, 156104265: 156104265
9 LMNA NM_170707.3(LMNA): c.608A> G (p.Glu203Gly) single nucleotide variant Pathogenic rs28933092 GRCh37 Chromosome 1, 156104288: 156104288
10 LMNA NM_170707.3(LMNA): c.481G> A (p.Glu161Lys) single nucleotide variant Pathogenic/Likely pathogenic rs28933093 GRCh37 Chromosome 1, 156100532: 156100532
11 DSP NM_004415.3(DSP): c.3799C> T (p.Arg1267Ter) single nucleotide variant Pathogenic/Likely pathogenic rs121912997 GRCh37 Chromosome 6, 7580222: 7580222
12 PSEN1 NM_000021.3(PSEN1): c.998A> G (p.Asp333Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121917809 GRCh37 Chromosome 14, 73678519: 73678519
13 BAG3 NM_004281.3(BAG3): c.367C> T (p.Arg123Ter) single nucleotide variant Pathogenic/Likely pathogenic rs387906875 GRCh37 Chromosome 10, 121429549: 121429549
14 TPM1 NM_001018005.1(TPM1): c.688G> A (p.Asp230Asn) single nucleotide variant Pathogenic rs199476317 GRCh37 Chromosome 15, 63354462: 63354462
15 LMNA NM_005572.3(LMNA): c.1003C> T (p.Arg335Trp) single nucleotide variant Pathogenic/Likely pathogenic rs386134243 GRCh37 Chromosome 1, 156105758: 156105758
16 SCN5A NM_198056.2(SCN5A): c.665G> A (p.Arg222Gln) single nucleotide variant Pathogenic rs45546039 GRCh37 Chromosome 3, 38655272: 38655272
17 MYH7 NM_000257.3(MYH7): c.1106G> A (p.Arg369Gln) single nucleotide variant Likely pathogenic rs397516089 GRCh37 Chromosome 14, 23899016: 23899016
18 MYH7 NM_000257.3(MYH7): c.5401G> A (p.Glu1801Lys) single nucleotide variant Likely pathogenic rs397516248 GRCh37 Chromosome 14, 23884362: 23884362
19 MYH7 NM_000257.3(MYH7): c.5740G> A (p.Glu1914Lys) single nucleotide variant Likely pathogenic rs397516254 GRCh37 Chromosome 14, 23883018: 23883018
20 TNNI3 NM_000363.4(TNNI3): c.544G> A (p.Glu182Lys) single nucleotide variant Pathogenic rs397516355 GRCh37 Chromosome 19, 55665403: 55665403
21 TNNT2 NM_001001430.2(TNNT2): c.392G> A (p.Arg131Gln) single nucleotide variant Pathogenic rs397516464 GRCh37 Chromosome 1, 201333493: 201333493
22 TNNT2 NM_001001430.2(TNNT2): c.629_631delAGA (p.Lys210del) deletion Pathogenic rs45578238 GRCh37 Chromosome 1, 201331099: 201331101
23 DES NM_001927.3(DES): c.38C> T (p.Ser13Phe) single nucleotide variant Pathogenic rs62636495 GRCh37 Chromosome 2, 220283222: 220283222
24 PLN NM_002667.4(PLN): c.40_42delAGA (p.Arg14del) deletion Pathogenic rs397516784 GRCh37 Chromosome 6, 118880124: 118880126
25 DSP NM_004415.3(DSP): c.1146delT (p.Phe382Leufs) deletion Pathogenic rs397516913 GRCh37 Chromosome 6, 7568019: 7568019
26 TTN NM_001256850.1(TTN): c.54282delG (p.Glu18094Aspfs) deletion Pathogenic/Likely pathogenic rs397517643 GRCh37 Chromosome 2, 179457641: 179457641
27 TTN NM_001267550.2(TTN): c.71602C> T (p.Arg23868Ter) single nucleotide variant Pathogenic/Likely pathogenic rs397517689 GRCh37 Chromosome 2, 179439257: 179439257
28 TTN NM_001267550.2(TTN): c.86821+2T> A single nucleotide variant Pathogenic/Likely pathogenic rs397517735 GRCh37 Chromosome 2, 179424036: 179424036
29 TTN NM_001256850.1(TTN): c.88974delT (p.Phe29658Leufs) deletion Pathogenic/Likely pathogenic rs397517758 GRCh37 Chromosome 2, 179412456: 179412456
30 LMNA NM_170707.3(LMNA): c.1112_1115dupTGGA (p.Glu372Aspfs) duplication Pathogenic/Likely pathogenic rs397517888 GRCh37 Chromosome 1, 156105867: 156105870
31 LMNA NM_170707.3(LMNA): c.1129C> T (p.Arg377Cys) single nucleotide variant Pathogenic/Likely pathogenic rs397517889 GRCh37 Chromosome 1, 156105884: 156105884
32 LMNA NM_005572.3(LMNA): c.1526dupC (p.Thr510Tyrfs) duplication Pathogenic/Likely pathogenic rs58013325 GRCh37 Chromosome 1, 156106941: 156106941
33 LMNA NM_170707.3(LMNA): c.1621C> T (p.Arg541Cys) single nucleotide variant Pathogenic rs56984562 GRCh37 Chromosome 1, 156107457: 156107457
34 LMNA NM_170707.3(LMNA): c.348_349insG (p.Lys117Glufs) insertion Pathogenic rs267607646 GRCh37 Chromosome 1, 156085057: 156085057
35 LMNA NM_170707.3(LMNA): c.607G> A (p.Glu203Lys) single nucleotide variant Pathogenic rs61195471 GRCh37 Chromosome 1, 156104287: 156104287
36 LMNA NM_005572.3(LMNA): c.673C> T (p.Arg225Ter) single nucleotide variant Pathogenic rs60682848 GRCh37 Chromosome 1, 156104629: 156104629
37 LMNA NM_170707.3(LMNA): c.781_783delAAG (p.Lys261del) deletion Pathogenic/Likely pathogenic rs58978449 GRCh37 Chromosome 1, 156104737: 156104739
38 LMNA NM_170707.3(LMNA): c.799T> C (p.Tyr267His) single nucleotide variant Pathogenic rs267607593 GRCh37 Chromosome 1, 156104755: 156104755
39 LMNA NM_170707.3(LMNA): c.949G> A (p.Glu317Lys) single nucleotide variant Pathogenic/Likely pathogenic rs56816490 GRCh37 Chromosome 1, 156105704: 156105704
40 LMNA NM_170707.3(LMNA): c.958delC (p.Leu320Phefs) deletion Pathogenic rs397517915 GRCh37 Chromosome 1, 156105713: 156105713
41 LMNA NM_170707.3(LMNA): c.961C> T (p.Arg321Ter) single nucleotide variant Pathogenic rs267607554 GRCh37 Chromosome 1, 156105716: 156105716
42 LMNA NM_170707.3(LMNA): c.992G> A (p.Arg331Gln) single nucleotide variant Pathogenic/Likely pathogenic rs59301204 GRCh37 Chromosome 1, 156105747: 156105747
43 DES NM_001927.3(DES): c.1360C> T (p.Arg454Trp) single nucleotide variant Pathogenic/Likely pathogenic rs267607490 GRCh37 Chromosome 2, 220290456: 220290456
44 LMNA NM_170707.3(LMNA): c.1294C> T (p.Gln432Ter) single nucleotide variant Pathogenic/Likely pathogenic rs267607618 GRCh37 Chromosome 1, 156106141: 156106141
45 LMNA NM_170707.3(LMNA): c.244G> A (p.Glu82Lys) single nucleotide variant Pathogenic rs59270054 GRCh37 Chromosome 1, 156084953: 156084953
46 SCN5A NM_198056.2(SCN5A): c.2440C> T (p.Arg814Trp) single nucleotide variant Pathogenic/Likely pathogenic rs199473161 GRCh37 Chromosome 3, 38627529: 38627529
47 DSP NM_004415.3(DSP): c.2131_2132delAG (p.Ser711Cysfs) deletion Pathogenic/Likely pathogenic rs587782927 GRCh37 Chromosome 6, 7574319: 7574320
48 TSFM NM_005726.5(TSFM): c.856C> T (p.Gln286Ter) single nucleotide variant Pathogenic/Likely pathogenic rs201754030 GRCh37 Chromosome 12, 58190244: 58190244
49 LMNA NM_170707.3(LMNA): c.1086delT (p.Leu363Trpfs) deletion Pathogenic rs58389804 GRCh37 Chromosome 1, 156105841: 156105841
50 LMNA NM_170707.3(LMNA): c.1609-1G> A single nucleotide variant Pathogenic/Likely pathogenic rs111569862 GRCh37 Chromosome 1, 156107444: 156107444

Expression for Dilated Cardiomyopathy

Search GEO for disease gene expression data for Dilated Cardiomyopathy.

Pathways for Dilated Cardiomyopathy

Pathways related to Dilated Cardiomyopathy according to KEGG:

36
# Name Kegg Source Accession
1 Dilated cardiomyopathy (DCM) hsa05414

Pathways related to Dilated Cardiomyopathy according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.65 DES MYBPC3 PLN SCN5A TNNI3 TNNT2
2
Show member pathways
12.59 ACTC1 MYH7 PLN SCN5A TNNI3 TNNT2
3 12.19 ACTC1 DES LMNA TMPO TNNI3 TNNT2
4
Show member pathways
12.16 DES DSP LMNA SGCD
5 11.64 DES TNNI3 TNNT2
6
Show member pathways
11.6 ACTC1 DES LMNA MYBPC3 MYH7 PLN
7 11.55 ACTC1 MYH7 TNNI3 TNNT2 TPM1
8 11.48 DSP LMNA PLN SCN5A
9 11.43 ACTC1 SCN5A TNNI3 TNNT2
10 11.36 ACTC1 DES MYBPC3 TNNI3 TNNT2 TPM1

GO Terms for Dilated Cardiomyopathy

Cellular components related to Dilated Cardiomyopathy according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 sarcolemma GO:0042383 9.67 DES SCN5A SGCD
2 Z disc GO:0030018 9.56 BAG3 CSRP3 DES LDB3 MYBPC3 MYH7
3 intercalated disc GO:0014704 9.54 DES DSP SCN5A
4 myosin filament GO:0032982 9.52 MYBPC3 MYH7
5 contractile fiber GO:0043292 9.51 DES TNNI3
6 myofibril GO:0030016 9.5 MYH7 TNNI3 TNNT2
7 cardiac myofibril GO:0097512 9.46 DES MYBPC3 TNNI3 TNNT2
8 fascia adherens GO:0005916 9.43 DES DSP
9 troponin complex GO:0005861 9.4 TNNI3 TNNT2
10 cardiac Troponin complex GO:1990584 9.26 TNNI3 TNNT2
11 sarcomere GO:0030017 9.17 ACTC1 CSRP3 MYBPC3 MYH7 TNNI3 TNNT2
12 cytoplasm GO:0005737 10.32 ACTC1 BAG3 CSRP3 DES DSP EYA4
13 cytoskeleton GO:0005856 10 ACTC1 CSRP3 DES DSP LDB3 SGCD

Biological processes related to Dilated Cardiomyopathy according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 cellular calcium ion homeostasis GO:0006874 9.77 CSRP3 PLN TNNI3
2 sarcomere organization GO:0045214 9.73 LDB3 MYBPC3 TPM1 TTN
3 muscle contraction GO:0006936 9.73 DES MYH7 TAZ TNNT2 TPM1 TTN
4 positive regulation of ATPase activity GO:0032781 9.71 MYBPC3 TNNT2 TPM1
5 regulation of heart contraction GO:0008016 9.71 DES PLN TNNT2 TPM1
6 regulation of the force of heart contraction GO:0002026 9.7 CSRP3 MYH7 PLN
7 regulation of muscle contraction GO:0006937 9.69 TNNI3 TNNT2 TPM1
8 heart contraction GO:0060047 9.67 ACTC1 SGCD TNNI3
9 striated muscle contraction GO:0006941 9.67 MYBPC3 MYH7 TNNI3 TTN
10 cardiac myofibril assembly GO:0055003 9.65 ACTC1 CSRP3 TTN
11 cardiac muscle contraction GO:0060048 9.65 ACTC1 CSRP3 MYBPC3 MYH7 SCN5A TAZ
12 negative regulation of ATPase activity GO:0032780 9.63 PLN TNNI3 TNNT2
13 cardiac muscle tissue development GO:0048738 9.62 CSRP3 PLN SGCD TAZ
14 intermediate filament organization GO:0045109 9.6 DES DSP
15 cardiac muscle tissue morphogenesis GO:0055008 9.58 ACTC1 TTN
16 regulation of cardiac muscle cell contraction GO:0086004 9.58 PLN SCN5A
17 cardiac muscle hypertrophy GO:0003300 9.57 CSRP3 TTN
18 skeletal muscle thin filament assembly GO:0030240 9.56 ACTC1 TTN
19 detection of muscle stretch GO:0035995 9.55 CSRP3 TTN
20 ventricular cardiac muscle tissue morphogenesis GO:0055010 9.55 MYBPC3 MYH7 TNNI3 TNNT2 TPM1
21 muscle filament sliding GO:0030049 9.23 ACTC1 DES MYBPC3 MYH7 TNNI3 TNNT2

Molecular functions related to Dilated Cardiomyopathy according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.97 CSRP3 DES MYBPC3 PLN TPM1 TTN
2 structural constituent of cytoskeleton GO:0005200 9.65 DES DSP TPM1
3 cytoskeletal protein binding GO:0008092 9.58 DES LDB3 TPM1
4 actin filament binding GO:0051015 9.55 MYBPC3 MYH7 TNNI3 TPM1 TTN
5 structural molecule activity conferring elasticity GO:0097493 9.46 MYBPC3 TTN
6 actinin binding GO:0042805 9.43 CSRP3 TTN
7 muscle alpha-actinin binding GO:0051371 9.43 LDB3 MYBPC3 TTN
8 actin binding GO:0003779 9.43 CSRP3 MYBPC3 MYH7 TNNI3 TNNT2 TPM1
9 telethonin binding GO:0031433 9.37 CSRP3 TTN
10 troponin C binding GO:0030172 9.32 TNNI3 TNNT2
11 structural constituent of muscle GO:0008307 8.92 CSRP3 MYBPC3 TPM1 TTN

Sources for Dilated Cardiomyopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....